fund details.

LO Funds

Golden Age, Syst. NAV Hdg, (CHF) P A

HIGHLIGHTS

LO Funds - Golden Age is an actively managed long-only global equity strategy launched in November 2009. It invests in companies deriving a significant portion of their revenues from the ageing population theme. It has a bias towards developed markets and towards the Healthcare, Consumer and Financial sectors. It seeks to outperform the MSCI World ND index over the long-term. The investment approach combines a fundamental bottom-up approach with a top down overlay to create a high conviction portfolio of around 50-70 positions. It focuses on names which should outperform the broader market on a sustainable basis and invests only in cash-flow positive companies that avoid significant binary risk. The portfolio style can be described as “Growth at a Reasonable Price”.

MANAGERS

Manager Profiles

Johan Utterman Zürich Investment Management (Global Equities)

Johan Utterman: Senior Portfolio Manager for LO Funds-Golden Age and Head of Swiss Equities Johan Utterman is the lead portfolio manager for the LO Funds–Golden Age fund and head of Swiss Equities at  Read more

Meret Gaugler Zürich Investment Management (Global Equities)

Dr.Meret Gaugler, Co-Portfolio Manager, LO Funds – Golden Age Meret Gaugler is co-portfolio manager for LO Funds – Golden Age and the Swiss Equities funds within Lombard Odier Investment Managers (LOIM)’s  Read more

GENERAL INFORMATION

Overview

Asset Class Equities
Category Global
Share Class reference currency CHF Hedged
Benchmark MSCI World ND (CHF Hdg. by LOIM)
Dividend Policy Accumulated

Latest Data

Performance YTD 2.78% 17.01.2020
Total Assets (all classes) in mn CHF 856.74 31.12.2019
Assets (share class) in mn CHF 9.17 31.12.2019
NAV (CHF) 26.59 17.01.2020
Highest - Last 12 months 26.59 17.01.2020
Lowest - Last 12 months 22.63 24.01.2019
Number of positions 55 31.12.2019
TER 1.85% 31.03.2019

Cumulative Performance

 
Past performance is not a guide to future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units, performance is presented net of fees. The NAV of fund units and official prices of benchmarks are used for performance comparison purposes. Source of the figures: Lombard Odier.

News & Awards

Awards

Provider year Distinction Period Sector
Lipper 2008 1st place 2008 Pharmaceuticals and Health Care

PRICES

Period
(Earliest Date: 01.06.2010)
(Latest date: 17.01.2020)

Prices over selected period

Last CHF 26.59 17.01.2020
First CHF 13.39 01.06.2010
Highest CHF 26.59 17.01.2020
Lowest CHF 11.97 25.11.2011

PERFORMANCE & STATISTICS

Statistics (01.06.2010 - 17.01.2020) ¹

( Earliest Date : 01.06.2010)
Go
( Latest date : 17.01.2020)
Fund Benchmark
Total Return 98.55% 130.65%
Annualized Return 7.35% 9.03%
Annualized Volatility 11.59% 12.58%
Sharpe Ratio 0.67 0.75
Downside Deviation 7.80% 7.98%
Positive Months 62.93% 65.52%
Maximum Drawdown -20.86% -20.63%
Fund vs Benchmark
Correlation 0.844
R2 0.712
Alpha 0.04%
Beta 0.777
Tracking Error 6.82%
Information Ratio -0.277
Risk-Free Rate -0.46% Target Rate -0.46%
¹ Calculations based on monthly time series

Cumulative Performance

 
Past performance is not a guide to future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units, performance is presented net of fees. The NAV of fund units and official prices of benchmarks are used for performance comparison purposes. Source of the figures: Lombard Odier.

BREAKDOWNS

Period

Top 10 (in %)

Roche
3.10%
Allergan
3.00%
Cigna
3.00%
Visa
3.00%
Lowe's
2.90%
Koninklijke DSM
2.80%
Zoetis
2.80%
Grifols
2.60%
Nestlé
2.50%
Zurich Insurance
2.30%

Sectors (in %)

Health care
46.80%
Financials
20.80%
Consumer discretionary
11.40%
Consumer staples
7.50%
Information technology
4.40%
Materials
4.10%
Real Estate
3.00%
Others (liquid assets incl.)
1.90%

Countries (in %)

United States
52.60%
Switzerland
12.70%
Others
9.80%
France
4.90%
Netherlands
4.90%
United Kingdom
4.90%
Denmark
3.40%
Spain
2.60%
China
2.30%
Liquid assets
1.90%

Increased (securities)

iShares Nsdq US Biotechnology UCITS ETF
1.50%
UBS
1.00%
Partners Group
0.80%
Halozyme Therapeutics
0.60%
Lindblad Expeditions
0.50%

SECURITY NUMBERS

Dealing

Subscriptions and redemptions frequency Daily
Subscriptions and redemptions cut-off day T-1
Subscriptions and redemptions cut-off time 15:00 CET
Subscriptions and redemptions settlement date T+2
NAV valuation point T
NAV calculation day T+1
NAV calculation frequency Daily
Minimum Investment EUR 3'000 or equivalent
Management Fee 0.75%
Distribution Fee 0.75%

Security Numbers

BLOOMBERG DHLIPAC LX
ISIN LU0504822510
REUTERS 11226081X.CHE
SEDOL GBB51V9F4
TELEKURS 11226081

Share Quotation

Electronic Media

DOCUMENTATION

Professional investors only Date DE EN FR IT
Newsletter IM - Professional 31.12.2019
Annexe Date DE EN FR IT
UK Reporting Status - Reportable Income 23.03.2017      
Reporting Date DE EN FR IT
Fact Sheet (marketing document) 31.12.2019
Performance Review 31.12.2019
Legal Documents Date DE EN FR IT
Articles of incorporation 21.03.2019    
Notice to Shareholders 17.04.2018    
Notice to Shareholders 28.08.2018      
Notice to Shareholders 05.02.2019    
Notice to Shareholders 21.02.2019    
Notice to Shareholders 12.03.2019    
Notice to Shareholders 10.12.2018    
Notice to Shareholders 17.09.2019      
Notice to Shareholders 30.01.2018    
Key Investor Information Document 18.07.2019
Prospectus 15.11.2019  
Annual Report 30.09.2018  
Semi-Annual Report 31.03.2019  
Sicav article of incorporation 21.03.2019  
Retail investors Date DE EN FR IT
Reasons to invest (Retail) 15.10.2019